Lucy Matthews

After completing her BSc (Hons) degree in Biochemistry with Neurobiology Lucy was a scientist for 12 years. After graduation she worked at the Forensic Science Service in London as an Assistant Forensic Scientist. She then gained a position as a research scientist at the Institute of Cancer Research (ICR) in Sutton specialising in prostate cancer. Lucy became involved in clinical trials at the ICR whilst working with the Drug Development Unit and Prostate Team at the Royal Marsden Hospital. She was responsible for coordinating the laboratory side of many biomarker based phase II clinical trials. Lucy joined the unit in December 2012 to focus on breast cancer studies. She is the QoL coordinator for many of our new breast cancer studies.


    Examines whether a short (8 min) film about Gene Expression Profiling (GEP) tests used in breast cancer (Oncotype DX® or Prosigna) helps improve patients‘ knowledge.


    A phase III trial of surgery versus active monitoring for Low Risk DCIS (LORIS), incorporating a two year feasibility study. The aim of the main trial is to determine whether women with newly diagnosed low risk DCIS can safely avoid surgery, without detriment to their psychological well-being and can those patients who do require surgery be identified by pathological and radiological criteria.


    A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes. The aim of this trial is to determine whether axillary clearance or radiotherapy can be safely avoided in women receiving chemotherapy and/or hormone therapy following surgery for early stage breast cancer. The trial also explores how aspects of QoL and psychological well-being are affected by fear of cancer recurrence and long term side effects of axillary treatment.

  • Jenkins V, Starkings R, Teoh M, May S, Bloomfield D, Zammit C, ... & Matthews L. (2023). Patients' views and experiences on the supported self-management/patient-initiated follow up pathway for breast cancer. Supportive Care in Cancer; 31(12): 658. Find it online here 27/10/2023
  • Wheelwright S, Matthews L, Jenkins V, May S, Rea D, Fairbrother P, Gaunt C, Young J, Pirrie S, Wallis M G, Fallowfield L, on behalf of the LORIS Trial Management Group (2023). Recruiting women with ductal carcinoma in situ to a randomised controlled trial: lessons from the LORIS study. Trials; 24(1): 670. Find it online here 14/10/2023
  • Jenkins V, Matthews L, Solis-Trapala I, Gage H, May S, Williams P, ... & Teoh M. (2023). Patients' experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC): quality of life and service use results. Supportive Care in Cancer; 31: 570 Find it online here 12/09/2023
  • Fallowfield L, Solis-Trapala I, Starkings R, May S, Matthews L, Eccles D, ... & Jenkins V. (2022). Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing. British Journal of Cancer; 127(6): 1116-1122. Find it online here 17/06/2022
  • Catt S, Matthews L, May S, Payne H, Mason M, & Jenkins V. (2019). Patients' and partners' views of care and treatment provided for metastatic castrate-resistant prostate cancer in the UK. European Journal of Cancer Care; 28(6): e13140. Find it online here 01/09/2019
  • Jenkins V, Solis-Trapala I, Payne H, Mason M, Fallowfield L, May S, ... & Catt S. (2019). Treatment experiences, information needs, pain and quality of life in men with metastatic castrate-resistant prostate cancer: results from the EXTREQOL study. Clinical Oncology; 31(2): 99-107. Find it online here 01/02/2019
  • Hinde S, Theriou C, May S, Matthews L, Arbon A, Fallowfield L, & Bloomfield D. (2019). The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Health Policy and Technology; 8(1): 75-83. Find it online here 24/12/2018
  • Jenkins V, Farewell V, May S, Catt S, Matthews L, Shilling V, ... & Fallowfield L. (2018). Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study. Supportive Care in Cancer; 26: 3941-3949. Find it online here 30/05/2018
  • Jenkins V, Payne H, Mason M, May S, Matthews L, & Catt S. (2018). EXTREQOL identifies ongoing challenges in maximising quality of survival in men with Metastatic Castrate-resistant Prostate Cancer. Clinical Oncology; 30(6): 331-333. Find it online here 16/02/2018
  • Fallowfield L, Matthews L, May S, Jenkins V, & Bloomfield D. (2018). Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing. Psycho-Oncology; 27(4): 1264-1269. Find it online here 15/02/2018